The partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in April 2026 via a Department of Justice order, providing tax and regulatory relief for qualifying operators while leaving recreational and unlicensed cannabis in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling concluded on July 15, 2026, after which the Chief Administrative Law Judge is expected to issue a recommendation later in 2026 before any final DEA Administrator decision. Recent D.C. Circuit rulings have allowed the medical changes to proceed amid ongoing challenges, but procedural steps, possible objections, and agency timelines introduce uncertainty for full rescheduling by year-end or early 2027. Trader positioning reflects these sequential hurdles and the lack of a finalized rule on wider cannabis classification.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour$809,958 Vol.
30 sept. 2026
30 septembre
4%
31 décembre
16%
$809,958 Vol.
30 septembre
$679 Vol.
4%
31 décembre
$199,708 Vol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in April 2026 via a Department of Justice order, providing tax and regulatory relief for qualifying operators while leaving recreational and unlicensed cannabis in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling concluded on July 15, 2026, after which the Chief Administrative Law Judge is expected to issue a recommendation later in 2026 before any final DEA Administrator decision. Recent D.C. Circuit rulings have allowed the medical changes to proceed amid ongoing challenges, but procedural steps, possible objections, and agency timelines introduce uncertainty for full rescheduling by year-end or early 2027. Trader positioning reflects these sequential hurdles and the lack of a finalized rule on wider cannabis classification.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Marché ouvert : Jul 31, 2026, 5:46 PM ET
Volume
$809,958Date de fin
1 janv. 2027Marché ouvert
Jul 31, 2026, 5:46 PM ETRésolveur
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in April 2026 via a Department of Justice order, providing tax and regulatory relief for qualifying operators while leaving recreational and unlicensed cannabis in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling concluded on July 15, 2026, after which the Chief Administrative Law Judge is expected to issue a recommendation later in 2026 before any final DEA Administrator decision. Recent D.C. Circuit rulings have allowed the medical changes to proceed amid ongoing challenges, but procedural steps, possible objections, and agency timelines introduce uncertainty for full rescheduling by year-end or early 2027. Trader positioning reflects these sequential hurdles and the lack of a finalized rule on wider cannabis classification.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$809,958Date de fin
1 janv. 2027Marché ouvert
Jul 31, 2026, 5:46 PM ETRésolveur
0x65070BE91...The partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in April 2026 via a Department of Justice order, providing tax and regulatory relief for qualifying operators while leaving recreational and unlicensed cannabis in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling concluded on July 15, 2026, after which the Chief Administrative Law Judge is expected to issue a recommendation later in 2026 before any final DEA Administrator decision. Recent D.C. Circuit rulings have allowed the medical changes to proceed amid ongoing challenges, but procedural steps, possible objections, and agency timelines introduce uncertainty for full rescheduling by year-end or early 2027. Trader positioning reflects these sequential hurdles and the lack of a finalized rule on wider cannabis classification.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes